GammaPix PK: Cost-effective, in-vivo monitoring & tracking of radio-nuclides

E.P. Rubenstein, G.A. Drukier, F. d’Errico
Image Insight Inc.,
United States

Keywords: in-vivo radio-nuclide tracking, drug discovery, nuclear medicine clearance monitoring


By harnessing the ability of smartphone and video cameras to sense gamma-ray interactions in their CMOS chips, GammaPix™ software measures radiation levels and computes their origin using multiple sensors. As ongoing research and development has enhanced the underlying technology, new application opportunities have emerged, including in the medical sector. Several uses across the biosciences are addressable by this inexpensive approach to measure the presence and in-vivo distribution of radio-isotopes. Broadly, there are three main areas: (1) drug discovery and development, (2) diagnostic pre-screening to assess suitability of patient for an expensive treatment, and (3) intra- and post-treatment assessment of biological clearance in nuclear medicine, and domicile monitoring of patient radiation levels. The use of common CMOS image sensors to address these medical applications opens up new opportunities for study. For example, consider a wearable sensor that incorporates several image chips allowing a researcher to follow the pharmacokinetics and mass balance of a trial drug for extended periods. The experiments to be discussed include comparing CMOS dose-response to standard Si sensors, multi-point monitoring of delivered dose both in phantoms and in-vivo, monitoring humans and cats following I-131 thyroid ablation treatment, and standard laboratory assessments of minimum detectable activity, sensitivity, etc. We will report results demonstrating the repeatability of readings for a given device, and the degree of consistency between devices of the same model. Finally, we will present data showing the ability to differentiate between gamma rays having different energies; this ability to classify emission based on photon energy has additional medical research and diagnostic applications.